NT-proBNP and sRAGE levels in early rheumatoid arthritis

References

• Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524–9.
   PubMed Web of Science ®Google Scholar
• Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005;52:412–20.
   PubMed Web of Science ®Google Scholar
• van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation. Ann Rheum Dis 2009;68:1395–400.
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Jacobsen SJ, Roger VL, et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:76–80.
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52:2293–9.
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722–32.
   PubMed Web of Science ®Google Scholar
• Kozera L, Andrews J, Morgan AW. Cardiovascular risk and rheumatoid arthritis–the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. Rheumatology (Oxford) 2011;50:1944–54.
   PubMed Web of Science ®Google Scholar
• Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005;7:817–24.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, et al. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol 2011;38:1071–8.
   PubMed Web of Science ®Google Scholar
• van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.
   PubMed Web of Science ®Google Scholar
• Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C, et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010;28:e53–64.
   PubMed Web of Science ®Google Scholar
• Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993;132:1961–70.
   PubMed Web of Science ®Google Scholar
• Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss H-P, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005;26:2277–84.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655–63.
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666–75.
   PubMed Web of Science ®Google Scholar
• Provan SA, Angel K, Odegard S, Mowinckel P, Atar D, Kvien TK, et al. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther 2008;10:R70.
   PubMed Web of Science ®Google Scholar
• Armstrong DJ, Gardiner PV, O’Kane MJ. Rheumatoid arthritis patients with active disease and no history of cardiac pathology have higher brain natriuretic peptide (BNP) levels than patients with inactive disease or healthy control subjects. Ulster Med J 2010;79:82–4.
   PubMedGoogle Scholar
• Provan S, Angel K, Semb AG, Atar D, Kvien TK. NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis 2010;69:1946–50.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011;1243:88–102.
   PubMed Web of Science ®Google Scholar
• Arsov S, Graaff R, van Oeveren W, Stegmayr B, Sikole A, Rakhorst G, et al. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Clin Chem Lab Med 2014;52:11–20.
   PubMed Web of Science ®Google Scholar
• Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103–13.
   PubMed Web of Science ®Google Scholar
• de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CG, Bijl M, et al. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Res Ther 2011;13:R205.
   PubMed Web of Science ®Google Scholar
• Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582–92.
   PubMed Web of Science ®Google Scholar
• Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995;147:654–67.
   PubMed Web of Science ®Google Scholar
• Parelsnoer Institute. [cited 2020 november 14]. Available fromhttps://parelsnoer.org/page/nl/Huidige-collecties?mod[Parelsnoer_Module_Pearl][n]=48
   Google Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LBA, Van Riel PLCM, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   PubMed Web of Science ®Google Scholar
• Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93–9.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948–54.
   PubMed Web of Science ®Google Scholar
• Nakhjavani MRJ, Jafarpour M, Ghorbanihaghjo A, Abedi Azar S, Malek Mahdavi A. Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients. Mod Rheumatol 2019;29:943–8.
   PubMed Web of Science ®Google Scholar
• Nadali M, Lyngfelt L, Erlandsson MC, Silfverswärd ST, Andersson KME, Bokarewa MI, et al. Low soluble receptor for advanced glycation end products precedes and predicts cardiometabolic events in women with rheumatoid arthritis. Front Med (Lausanne) 2021;7:594622.
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang JT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;11:1278–83.
   Web of Science ®Google Scholar
• Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-terminal pro–B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019;322:1085–95.
   PubMed Web of Science ®Google Scholar
• Taylor CJ BMJ, Roalfe AK, Iles R, Hobbs FDR. The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis. BMJ Open 2014;4:e004675.
   PubMed Web of Science ®Google Scholar